6,205 Shares in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Acquired by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC bought a new stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 6,205 shares of the medical device company’s stock, valued at approximately $263,000.

Several other hedge funds have also made changes to their positions in the company. Assetmark Inc. bought a new position in Tandem Diabetes Care during the 3rd quarter worth about $29,000. ORG Wealth Partners LLC bought a new position in shares of Tandem Diabetes Care during the third quarter valued at approximately $30,000. ORG Partners LLC purchased a new position in Tandem Diabetes Care during the second quarter valued at approximately $31,000. Waldron Private Wealth LLC purchased a new position in Tandem Diabetes Care during the third quarter valued at approximately $50,000. Finally, Headlands Technologies LLC raised its stake in Tandem Diabetes Care by 110.0% in the second quarter. Headlands Technologies LLC now owns 2,060 shares of the medical device company’s stock worth $83,000 after buying an additional 1,079 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Sanford C. Bernstein began coverage on Tandem Diabetes Care in a report on Wednesday, November 6th. They issued an “outperform” rating and a $42.00 price target on the stock. Royal Bank of Canada initiated coverage on Tandem Diabetes Care in a research note on Wednesday, October 2nd. They issued an “outperform” rating and a $65.00 target price on the stock. Morgan Stanley reaffirmed an “equal weight” rating and issued a $45.00 price objective on shares of Tandem Diabetes Care in a research report on Monday, September 23rd. Canaccord Genuity Group decreased their target price on shares of Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Finally, Wells Fargo & Company lifted their price target on shares of Tandem Diabetes Care from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Five investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, Tandem Diabetes Care has an average rating of “Moderate Buy” and a consensus price target of $54.25.

Tandem Diabetes Care Stock Performance

Shares of NASDAQ TNDM opened at $28.76 on Tuesday. The company’s fifty day moving average price is $37.46 and its 200 day moving average price is $41.68. The company has a market capitalization of $1.89 billion, a PE ratio of -14.90 and a beta of 1.36. Tandem Diabetes Care, Inc. has a 1 year low of $17.33 and a 1 year high of $53.69. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings results on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.08. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The company had revenue of $243.97 million during the quarter, compared to analysts’ expectations of $224.14 million. During the same quarter in the prior year, the firm posted ($0.38) EPS. Tandem Diabetes Care’s quarterly revenue was up 31.4% compared to the same quarter last year. On average, research analysts predict that Tandem Diabetes Care, Inc. will post -1.73 earnings per share for the current year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.